LENALIDOMIDE a thalidomide analogue, is an immunomodulatory agent with antiangiogenic and antineoplastic properties.
LENALIDOMIDE in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).
LENALIDOMIDE is indicated as maintenance therapy in patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).
LENALIDOMIDE is indicated for the treatment of patients with transfusion dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
LENALIDOMIDE is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included Bortezomib.
IMPORTANT SAFETY INFORMATION
Pregnancy: LENALIDOMIDE can cause fetal harm when administered to a pregnant female. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Severe Hypersensitivity Reactions LENALIDOMIDE is contraindicated in patients who have demonstrated hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide.